Clinical Trial

Phase III Radium 223 mCRPC-PEACE III

Study acronym: PEACE III
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2014-07-17; most recent amendment 2025-09-15.
Status change: Recruiting → Active, Not Recruiting 2023-03-29
Status change: Not Yet Recruiting → Recruiting 2015-10-26
Trial Details
NCT Number NCT02194842
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Conditions Prostate Cancer
Enrollment 446 participants
Start Date 2015-10
Primary Completion 2024-02-19 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-19